Clinical Trial Update: Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase II trial results for sunitinib malate in metastatic or surgically unresectable soft tissue sarcoma were posted, evaluating activity across several sarcoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrosarcoma
• Leiomyosarcoma
• Liposarcoma
• Undifferentiated Pleomorphic Sarcoma

Drugs mentioned

• Sunitinib malate (Sutent) (sunitinib malate)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Liposarcoma, Leiomyosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2012-08-28